Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Status:
Terminated
Trial end date:
2016-08-26
Target enrollment:
Participant gender:
Summary
There is a medical need for improving treatment of poor performance status patients with EGFR
driver mutations and documenting safety and tolerability of existing agents.